Keywords
Rituximab
Treatment
Cost-benefit
Neurology
How to Cite
Abstract
Multiple sclerosis (MS) is a debilitating neurodegenerative disease in which antibodies attack the myelin sheath of neurons in the central nervous system. Rituximab is an anti-CD20 monoclonal antibody that causes loss of BL, reducing the number of defense cells capable of attacking the myelin sheaths of neurons in the central nervous system, thus preventing flare-ups, especially in patients refractory to first-line treatment.
References
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod e dimetil fumarato no tratamento da esclerose múltipla. Annals of Clinical and Translational Neurology. 2020;7(9):1466-1476. https://doi.org/10.1002/acn3.51120
Claverie R, Perriguey M, Rico A, et al. Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?. Neurol Neuroimmunol Neuroinflamm. 2023;10(5):e200152. https://doi.org/10.1212/NXI.0000000000200152
Zhong M, van der Walt A, Campagna MP, Stankovich J, Butzkueven H, Jokubaitis V. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis. Neurotherapeutics. 2020;17(4):1768-1784. https://doi.org/10.1007/s13311-020-00923-6
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269(1):159-183. https://doi.org/10.1007/s00415-021-10691-0
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Global Academic Nursing Journal